Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India talks tough to end trade margins row as drug shortages loom

This article was originally published in SRA

Executive Summary

Faced with the prospect of continued disruptions to shipments of essential medicines in India from a disagreement over trade margins, the country's department of pharmaceuticals (DoP) has taken a tough stance, urging state governments to ensure smooth supplies, including by invoking the Essential Commodities Act if necessary.

You may also be interested in...



With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

BI India’s First Woman MD May Have To Hit The Ground Running

The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.

Research Preprints: Pharma’s Slow Embrace And Predicament

Pharma appears to be treading carefully when it comes to research preprints but COVID-19 has spotlighted the role of these pre-peer-reviewed papers during public health emergencies.

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel